Ionovol (Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Sodium Acetate Trihydrate)

The magnesium chloride, potassium chloride, sodium chloride and sodium acetate in Ionovol dissociate in the bloodstream, delivering essential cations and anions. Magnesium supports enzymatic reactions, potassium maintains cellular membrane potential, sodium contributes to extracellular fluid volume, and acetate is metabolized to bicarbonate, helping correct acid‑base disturbances.

The dosage of Ionovol is individualized by the prescribing clinician based on the patient’s electrolyte deficits, fluid status, and clinical condition. The prescriber determines the infusion rate, total volume, and duration according to laboratory values and therapeutic goals. No standard dose is provided here.

The safety of Ionovol during pregnancy and lactation has not been fully established, and the product lacks a specific pregnancy category. Use in pregnant or nursing women should be considered only if the potential benefit justifies the potential risk, and it must be prescribed and monitored by a qualified healthcare professional.

To order Ionovol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

The primary alternative to Ionovol is other IV electrolyte solutions such as Ringer’s lactate or normal saline combined with separate electrolyte supplements. Ionovol offers a balanced combination of magnesium, potassium, sodium, and acetate in a single formulation, which can simplify dosing and reduce the need for multiple infusions compared with using separate solutions.

Ionovol should be stored at controlled room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. The container must be kept sealed until use, and any solution that appears discolored or contains particles should be discarded. No refrigeration is required.

Ionovol is administered intravenously as a sterile solution for injection. The infusion is typically delivered through a calibrated IV set, with the rate adjusted according to the patient’s electrolyte levels and clinical response. Administration should be performed by trained healthcare personnel in a setting equipped for monitoring vital signs and potential infusion reactions.

The most serious risks associated with Ionovol include severe hypermagnesemia or hyperkalemia, which can cause cardiac arrhythmias, respiratory depression, or hypotension, as well as anaphylactic or severe allergic reactions. Prompt monitoring of electrolyte concentrations, cardiac function, and infusion site is essential to detect and manage these complications early.

Ionovol should be avoided in patients with known hypersensitivity to any of its components, those with severe renal impairment where electrolyte excretion is compromised, and individuals with existing life‑threatening hypermagnesemia, hyperkalemia, or hypernatremia. It is also contraindicated when concurrent administration of incompatible IV solutions could cause precipitation.